Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flepp

Showing results (61-70 of 111) with videos related to

Pageof 12
Sort By:
Medical Image Analysis|May 26, 2026
NeuralBoneReg: An instance-specific label-free point cloud-based method for multi-modal bone surface registrationLuohong Wu, Matthias Seibold, Nicola A Cavalcanti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 26, 2003
Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxisChristina Eigenmann, Markus Flepp, Enos Bernasconi, et al.
Virology|July 21, 2004
Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocolPeter Rusert, Marek Fischer, Beda Joos, et al.
Journal of Cardiac Surgery|April 21, 2021
Late outcome after surgical and topical treatment for Aspergillus mediastinitis after heart transplantationPaul R Vogt, Raed Aser, Daniel Schmidlin, et al.
Annals of Internal Medicine|November 15, 1991
Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. The Swiss HIV Cohort StudyA Heald, M Flepp, J P Chave, et al.
Journal of Medical Virology|July 19, 2006
HIV replication elicits little cytopathic effects in vivo: analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell deathGeorg A Funk, Annette Oxenius, Marek Fischer, et al.
BMJ (Clinical Research Ed.)|December 11, 1997
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort StudyM Egger, B Hirschel, P Francioli, et al.
AIDS (London, England)|October 2, 2001
Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort StudyA C Friedl, B Ledergerber, M Flepp, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 16, 2006
Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapyS Bertschy, M Opravil, M Cavassini, et al.
AIDS (London, England)|December 28, 2000
Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapyA C Friedl, C H Attenhofer Jost, C Schalcher, et al.
Pageof 12

Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
Medical Image Analysis|May 26, 2026
NeuralBoneReg: An instance-specific label-free point cloud-based method for multi-modal bone surface registrationLuohong Wu, Matthias Seibold, Nicola A Cavalcanti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 26, 2003
Low incidence of community-acquired pneumonia among human immunodeficiency virus-infected patients after interruption of Pneumocystis carinii pneumonia prophylaxisChristina Eigenmann, Markus Flepp, Enos Bernasconi, et al.
Virology|July 21, 2004
Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocolPeter Rusert, Marek Fischer, Beda Joos, et al.
Journal of Cardiac Surgery|April 21, 2021
Late outcome after surgical and topical treatment for Aspergillus mediastinitis after heart transplantationPaul R Vogt, Raed Aser, Daniel Schmidlin, et al.
Annals of Internal Medicine|November 15, 1991
Treatment for cerebral toxoplasmosis protects against Pneumocystis carinii pneumonia in patients with AIDS. The Swiss HIV Cohort StudyA Heald, M Flepp, J P Chave, et al.
Journal of Medical Virology|July 19, 2006
HIV replication elicits little cytopathic effects in vivo: analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell deathGeorg A Funk, Annette Oxenius, Marek Fischer, et al.
BMJ (Clinical Research Ed.)|December 11, 1997
Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort StudyM Egger, B Hirschel, P Francioli, et al.
AIDS (London, England)|October 2, 2001
Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort StudyA C Friedl, B Ledergerber, M Flepp, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 16, 2006
Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapyS Bertschy, M Opravil, M Cavassini, et al.
AIDS (London, England)|December 28, 2000
Acceleration of confirmed coronary artery disease among HIV-infected patients on potent antiretroviral therapyA C Friedl, C H Attenhofer Jost, C Schalcher, et al.
Pageof 12